403 related articles for article (PubMed ID: 23442835)
1. Obesity does not affect treatment outcomes with proton pump inhibitors.
Sharma P; Vakil N; Monyak JT; Silberg DG
J Clin Gastroenterol; 2013 Sep; 47(8):672-7. PubMed ID: 23442835
[TBL] [Abstract][Full Text] [Related]
2. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
Sharma P; Johnson DA; Monyak JT; Illueca M
Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
[TBL] [Abstract][Full Text] [Related]
3. Heartburn severity does not predict disease severity in patients with erosive esophagitis.
Fennerty MB; Johnson DA
MedGenMed; 2006 Apr; 8(2):6. PubMed ID: 16926745
[TBL] [Abstract][Full Text] [Related]
4. The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
Aliment Pharmacol Ther; 2013 Apr; 37(8):810-8. PubMed ID: 23451835
[TBL] [Abstract][Full Text] [Related]
5. Predictors of heartburn resolution and erosive esophagitis in patients with GERD.
Orlando RC; Monyak JT; Silberg DG
Curr Med Res Opin; 2009 Sep; 25(9):2091-102. PubMed ID: 19601705
[TBL] [Abstract][Full Text] [Related]
6. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
Aliment Pharmacol Ther; 2013 Nov; 38(10):1303-11. PubMed ID: 24118079
[TBL] [Abstract][Full Text] [Related]
7. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
Bytzer P; van Zanten SV; Mattsson H; Wernersson B
Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
[TBL] [Abstract][Full Text] [Related]
8. Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole.
Pace F; Coudsy B; DeLemos B; Sun Y; Xiang J; LoCoco J; Casalini S; Li H; Pelosini I; Scarpignato C
Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):845-51. PubMed ID: 21900784
[TBL] [Abstract][Full Text] [Related]
9. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies.
Laine L; Katz PO; Johnson DA; Ibegbu I; Goldstein MJ; Chou C; Rossiter G; Lu Y
Aliment Pharmacol Ther; 2011 Jan; 33(2):203-12. PubMed ID: 21114792
[TBL] [Abstract][Full Text] [Related]
10. Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.
Hongo M; Miwa H; Kusano M;
J Gastroenterol Hepatol; 2012 May; 27(5):913-8. PubMed ID: 22142515
[TBL] [Abstract][Full Text] [Related]
11. Association of body mass index with heartburn, regurgitation and esophagitis: results of the Progression of Gastroesophageal Reflux Disease study.
Nocon M; Labenz J; Jaspersen D; Meyer-Sabellek W; Stolte M; Lind T; Malfertheiner P; Willich SN
J Gastroenterol Hepatol; 2007 Nov; 22(11):1728-31. PubMed ID: 17914941
[TBL] [Abstract][Full Text] [Related]
12. Refractory GERD: increased body mass index is associated with persisting acid exposure but not hypersensitive esophagus or functional heartburn.
Viazis N; Karamanolis GP; Anastasiou J; Keyoglou A; Vlachogiannakos J; Ladas SD; Karamanolis DG
Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1450-5. PubMed ID: 24047861
[TBL] [Abstract][Full Text] [Related]
13. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
Johnson DA; Benjamin SB; Vakil NB; Goldstein JL; Lamet M; Whipple J; Damico D; Hamelin B
Am J Gastroenterol; 2001 Jan; 96(1):27-34. PubMed ID: 11197282
[TBL] [Abstract][Full Text] [Related]
14. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.
Castell DO; Kahrilas PJ; Richter JE; Vakil NB; Johnson DA; Zuckerman S; Skammer W; Levine JG
Am J Gastroenterol; 2002 Mar; 97(3):575-83. PubMed ID: 11922549
[TBL] [Abstract][Full Text] [Related]
15. Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
Emerson CR; Marzella N
Clin Ther; 2010 Aug; 32(9):1578-96. PubMed ID: 20974316
[TBL] [Abstract][Full Text] [Related]
16. Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment.
Poh CH; Gasiorowska A; Navarro-Rodriguez T; Willis MR; Hargadon D; Noelck N; Mohler J; Wendel CS; Fass R
Gastrointest Endosc; 2010 Jan; 71(1):28-34. PubMed ID: 19922918
[TBL] [Abstract][Full Text] [Related]
17. Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis.
Yaghoobi M; Padol S; Yuan Y; Hunt RH
Eur J Gastroenterol Hepatol; 2010 May; 22(5):583-90. PubMed ID: 20061959
[TBL] [Abstract][Full Text] [Related]
18. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease.
Wu JC; Lai LH; Chow DK; Wong GL; Sung JJ; Chan FK
Neurogastroenterol Motil; 2011 Feb; 23(2):155-60, e31. PubMed ID: 21087355
[TBL] [Abstract][Full Text] [Related]
19. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study.
Labenz J; Armstrong D; Lauritsen K; Katelaris P; Schmidt S; Schütze K; Wallner G; Juergens H; Preiksaitis H; Keeling N; Nauclér E; Eklund S;
Aliment Pharmacol Ther; 2005 Mar; 21(6):739-46. PubMed ID: 15771760
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis.
Fennerty MB; Johanson JF; Hwang C; Sostek M
Aliment Pharmacol Ther; 2005 Feb; 21(4):455-63. PubMed ID: 15709997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
